Skip to main content

Antibacterial activity of carbapenems against clinical isolates of respiratory bacterial pathogens in the northeastern region of Japan in 2007

Abstract

As the increasing prevalence of resistant strains of respiratory bacterial pathogens has recently been reported, continuous monitoring of the susceptibility of clinical isolates to antibacterial agents is important. We performed a surveillance study focusing on the susceptibility of major respiratory bacterial pathogens in the northeastern region of Japan to carbapenems and control drugs. A total of 168 bacterial strains isolated from patients with respiratory tract infections in 2007 were collected and the minimum inhibitory concentration (MIC) determined. MIC data were subjected to pharmacokinetic/pharmacodynamic analysis with Monte Carlo simulation to calculate the probability of achieving the target of time above MIC with each carbapenem. All Moraxella catarrhalis, Streptococcus pneumoniae, and methicillin-sensitive Staphylococcus aureus isolates were susceptible to carbapenems. Despite the increasing prevalence of β-lactamase-nonproducing ampicillin-resistant strains, all Haemophilus influenzae isolates were susceptible to meropenem. For Pseudomonas aeruginosa, the susceptibility rates for meropenem and biapenem were 76.7%, and the highest probability of achieving pharmacodynamic target (40% of the time above MIC) was obtained with meropenem 0.5 g three times daily as a 4-h infusion (89.4%), followed by meropenem 0.5 g four times daily as a 1-h infusion (88.4%). Carbapenems have retained their position as key drugs for severe respiratory tract infections.

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. The Committee for the Japanese Respiratory Society guidelines in the management of respiratory infections. The Japanese Respiratory Society guidelines for the management of hospital-acquired pneumonia in adults. Respirology. 2004;9 Suppl 1:S1–S62.

    Google Scholar 

  2. The Committee for the Japanese Respiratory Society guidelines in the management of respiratory infections. The Japanese Respiratory Society guidelines for the management of community-acquired pneumonia in adults. Respirology. 2006;11 Suppl 3:S79–S133.

    Google Scholar 

  3. Ubukata K. Problems associated with high prevalence of multidrug-resistant bacteria in patients with community-acquired infections. J Infect Chemother. 2003;9:285–91.

    PubMed  Article  Google Scholar 

  4. Watanabe A, Yanagihara K, Kohno S, Matsushima T. HAP study group. Multicenter survey on hospital-acquired pneumonia and the clinical efficacy of first-line antibiotics in Japan. Intern Med. 2008;47:245–54.

    PubMed  Article  Google Scholar 

  5. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo β-lactamases: the quiet before the storm? Clin Microbiol Rev. 2005;18:306–25.

    PubMed  Article  CAS  Google Scholar 

  6. Committee for Revision of MIC Determination Method. Revision of minimal inhibitory concentration (MIC) determination method (in Japanese). Chemotherapy (Tokyo). 1990;38:102–5.

    Google Scholar 

  7. Saito A, Inamatsu T, Okada J, Oguri T, Kanno H, Kusano N, et al. Clinical breakpoints in pulmonary infections and sepsis: new antimicrobial agents and supplemental information for some agents already released. J Infect Chemother. 1999;5:223–6.

    PubMed  Article  CAS  Google Scholar 

  8. Kadota J, Ishii Y, Kusachi S, Kusano N, Niki Y, Higa F, et al. Clinical breakpoints in pulmonary infections, sepsis and urinary tract infections: addition of new antimicrobial agents (2009). Jpn J Chemother. 2009;57:343–5. (in Japanese).

    Google Scholar 

  9. O’Callaghan CH, Morris A, Kirby SM, Shingler AH. Novel method for detection of β-lactamases by using a chromogenic cephalosporin substrate. Antimicrob Agents Chemother. 1972;1:283–8.

    PubMed  Google Scholar 

  10. Arakawa Y, Shibata N, Shibayama K, Kurokawa H, Yagi T, Fujiwara H, et al. Convenient test for screening metallo-β-lactamase-producing gram-negative bacteria by using thiol compounds. J Clin Microbiol. 2000;38:40–3.

    PubMed  CAS  Google Scholar 

  11. Hasegawa K, Yamamoto K, Chiba N, Kobayashi R, Nagai K, Jacobs MR, et al. Diversity of ampicillin-resistance genes in Haemophilus influenzae in Japan and the United States. Microb Drug Resist. 2003;9:39–46.

    PubMed  Article  CAS  Google Scholar 

  12. Ubukata K, Chiba N, Hasegawa K, Kobayashi R, Iwata S, Sunakawa K. Antibiotic susceptibility in relation to penicillin-binding protein genes and serotype distribution of Streptococcus pneumoniae strains responsible for meningitis in Japan, 1999 to 2002. Antimicrob Agents Chemother. 2004;48:1488–94.

    PubMed  Article  CAS  Google Scholar 

  13. Watanabe A, Fujimura S, Kikuchi T, Gomi K, Fuse K, Nukiwa T. Evaluation of dosing designs of carbapenems for severe respiratory infection using Monte Carlo simulation. J Infect Chemother. 2007;13:332–40.

    PubMed  Article  CAS  Google Scholar 

  14. Kuti JL, Ong C, Lo M, Melnick D, Soto N, Nicolau DP. Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections. Int J Antimicrob Agents. 2006;28:62–8.

    PubMed  Article  CAS  Google Scholar 

  15. Saito A, Kohno S, Matsushima T, Watanabe A, Oizumi K, Yamaguchi K, et al. Prospective multicenter study of the causative organisms of community-acquired pneumonia in adults in Japan. J Infect Chemother. 2006;12:63–9.

    PubMed  Article  Google Scholar 

  16. Gomi K, Watanabe A, Aoki S, Kikuchi T, Fuse K, Nukiwa T, et al. Antibacterial activity of carbapenems against clinically isolated respiratory bacterial pathogens in Japan between 2005 and 2006. Int J Antimicrob Agents. 2007;29:586–92.

    PubMed  Article  CAS  Google Scholar 

  17. Hasegawa K, Chiba N, Kobayashi R, Murayama SY, Iwata S, Sunakawa K, et al. Rapidly increasing prevalence of β-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae type b in patients with meningitis. Antimicrob Agents Chemother. 2004;48:1509–14.

    PubMed  Article  CAS  Google Scholar 

  18. Kanazawa K, Nouda K, Sunagawa M. Structure-activity relationships of carbapenem compounds to anti-Haemophilus influenzae activity and affinity for penicillin-binding proteins: effect of 1-methyl group and C-2 side chain. J Antibiot. 1997;50:162–8.

    PubMed  CAS  Google Scholar 

  19. Seki M, Watanabe A, Mikasa K, Kadota J, Kohno S. Revision of the severity rating and classification of hospital-acquired pneumonia in the Japanese Respiratory Society Guidelines. Respirology. 2008;13:880–5.

    PubMed  Article  Google Scholar 

  20. The Committee for the Japanese Respiratory Society guidelines in the management of respiratory infections. The Japanese Respiratory Society guidelines for the management of hospital-acquired pneumonia in adults. Respirology. 2009;14 Suppl 2:S1–S71.

    Google Scholar 

  21. Niki Y, Hanaki H, Matsumoto T, Yagisawa M, Kohno S, Aoki N, et al. Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2007: general view of the pathogens’ antibacterial susceptibility. J Infect Chemother. 2009;15:156–67.

    PubMed  Article  CAS  Google Scholar 

  22. Sumita Y, Fukasawa M. Meropenem resistance in Pseudomonas aeruginosa. Chemotherapy. 1996;42:47–56.

    PubMed  Article  CAS  Google Scholar 

  23. Watanabe A, Kikuchi H, Kikuchi T, Lutfor AB, Tokue Y, Takahashi H, et al. Comparative in vitro activity of carbapenem antibiotics against respiratory pathogens isolated in recent years. J Infect Chemother. 1999;5:171–5.

    PubMed  Article  CAS  Google Scholar 

  24. Watanabe A, Tokue Y, Takahashi H, Kikuchi T, Kobayashi T, Gomi K, et al. Comparative in vitro activity of carbapenem antibiotics against respiratory pathogens isolated between 1999 and 2000. J Infect Chemother. 2001;7:267–71.

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported partially by a grant from Dainippon Sumitomo Pharma.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Akira Watanabe.

About this article

Cite this article

Gomi, K., Fujimura, S., Fuse, K. et al. Antibacterial activity of carbapenems against clinical isolates of respiratory bacterial pathogens in the northeastern region of Japan in 2007. J Infect Chemother 17, 200–206 (2011). https://doi.org/10.1007/s10156-010-0112-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10156-010-0112-2

Keywords

  • Carbapenem
  • Antibacterial susceptibility
  • Respiratory tract infection (RTI)